Nicolau J C, Braile D M, de Araújo J D, Garzon S A, Lesse A P, Coelho W M, Cardoso H A, Thevenard R S, Bizelli M L, Greco O T
Instituto de Moléstias Cardiovasculares, São José do Rio Preto, SP.
Arq Bras Cardiol. 1991 Jun;56(6):493-7.
Utilization of fibrinolytic drugs in non-coronary diseases has been described since 1949, but despite of that, works about that subject are very rare in the literature. In this paper we discuss the cases of three patients that were treated with such compounds for pulmonary embolism, peripheral arterial embolism, and thrombosis in mechanical aortic prosthesis. All patients had excellent in-hospital outcome, and were totally asymptomatic at the discharge time. It is emphasized the clinical symptoms, sometimes unexpected, and the importance of the complementary tests not only in the disease's diagnosis, but also in some decisions that must be taken during the patient's evolution, where they can help us to decide, for example, about the correct moment to stop the thrombolytic infusion. In conclusion, fibrinolytic drugs can be utilized in the management of many affections that otherwise would be treated by emergency surgery.
自1949年以来，已有关于纤维蛋白溶解药物在非冠状动脉疾病中应用的描述，但尽管如此，文献中关于该主题的研究非常罕见。在本文中，我们讨论了三名使用此类化合物治疗肺栓塞、外周动脉栓塞和机械主动脉瓣假体血栓形成的患者病例。所有患者住院期间预后良好，出院时完全无症状。强调了临床症状，有时是意想不到的症状，以及辅助检查的重要性，这些检查不仅在疾病诊断中，而且在患者病情发展过程中必须做出的一些决策中都很重要，例如，它们可以帮助我们决定停止溶栓输注的正确时机。总之，纤维蛋白溶解药物可用于治疗许多原本需要急诊手术治疗的疾病。
